Items tagged with Drug-susceptible TB
The World Health Organization (WHO) is convening a Guideline Development Group (GDG) to advise on updates needed to its recommendations on the treatment of drug susceptible tuberculosis (TB).
14 June 2021, Geneva | A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme announced updates to the current treatment regimen for people with TB. A review of evidence by WHO has shown similar performance of a shorter treatment regimen compared to the current standard regimen, both in terms of efficacy and safety. The 4-month regimen, which is shorter, effective and all-oral, would be a preference for many patients and also national TB programmes, allowing faster cure and easing the burden on both patients and the healthcare system. Shortened treatment has the potential to improve adherence and reduce patient and health system costs.
Otsuka awarded grant for Phase 2 trial combining novel anti-tuberculosis compound OPC-167832 with delamanid and bedaquiline (post)
-- Grant up to $17.8 million will support study of treatment-shortening regimen in drug-sensitive tuberculosis (DS-TB)
-- Study expected to begin in 2022 evaluating safety and efficacy of novel 3-drug combination versus existing 4-drug standard of care
Target product profile for next-generation TB drug-susceptibility testing at peripheral sites (post)
10 August 2021 | Geneva - The World Health Organization (WHO) is launching its updated target product profile (TPP) for next-generation drug-susceptibility (DST) testing for M. tuberculosis at peripheral centres.
10 November 2021: The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5362 (CLO-FAST), a clinical trial studying a three-month clofazimine- and high-dose rifapentine-containing treatment regimen for people with drug-susceptible tuberculosis (TB). This is the first TB regimen based on preclinical evidence of effectiveness that is less than four-months long to be studied in a clinical trial. A5362 will evaluate the potential efficacy of clofazimine when combined with treatments that have been proven to be effective against TB.
The CDC published a recommendation and interim guidance in MMWR for a 4-month regimen to treat patients aged 12 years or older with drug-susceptible pulmonary tuberculosis.
CROI 2022 TB round up (post)
Treatment Action Group (TAG) released an overview of TB data reported at the 29th Conference on Retroviruses and Opportunistic Infections (CROI 2022) held virtually on 12-16 February 2022. A summary of major findings and TAG’s take on them are available here.
May 16, 2022 – We applaud the New York City Department of Health and Mental Hygiene (DoHMH) for its leadership as one of the first TB programs in the U.S. and globally to introduce a new four-month regimen for the treatment of drug-susceptible tuberculosis (TB). This new regimen represents a long-awaited breakthrough, offering a shorter alternative to the six-to-nine-month treatment in use since the 1980s. That the Department of Health and Mental Hygiene is moving forward to make this regimen available to patients will make treatment more tolerable for people living with TB. As TB survivor and activist Kate O’Brien of We Are TB and co-chair of the TB Roundtable put it, “TB treatment can be such a miserable experience, with all sorts of side effects and logistical complications. Shorter regimens offer patients welcome relief and I’m thrilled to see important government investments delivering better cures for TB.”
Chennai, Jul 4: ICMR’s National Institute for Research in Tuberculosis has initiated a study to assess the efficacy of a four-month tuberculosis treatment regimen as compared to the existing six-month regimen.
On February 24, 2022, the Centers for Disease Control and Prevention (CDC) published new interim guidance in Morbidity and Mortality Weekly Report on a 4-month treatment regimen as an option for US patients with drug-susceptible pulmonary tuberculosis (TB). The 4-month treatment regimen consists of high-dose daily rifapentine with moxifloxacin, isoniazid, and pyrazinamide. Shorter regimens help patients complete treatment faster.
Page 2 of 4 · Total posts: 0←First 1 2 3 Last→